Last checked at 11 Oct 2017 13:31
11 October 2017 | AIM: RENE |
ReNeuron Group plc
Director/PDMR Interest in Shares and Share Options
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that, on 9 October 2017, the following grants made on 11 September 2017 under the Company's Long Term Incentive Plan (LTIP) were deemed accepted by the relevant Persons Discharging Managerial Responsibilities (PDMRs). Share option grants made to Directors on 11 September 2017, which were separately announced by RNS on 12 September 2017, were also deemed accepted by those Directors on 9 October 2017. Under the terms of the grants, 9 October 2017 was the final day by which grantees could decline the option granted to them on 11 September 2017.
Name | Title | Date of grant of LTIP share options | Date LTIP share options accepted | Number of LTIP share options granted & accepted | Total shares over which options are held | Percentage of issued shares under option |
Randolph Corteling | Head of Research | 11 Sept 17 | 9 Oct 17 | 3,000,000 | 12,604,041 | 0.40% |
Sharon Grimster | VP Development & General Manager - Wales | 11 Sept 17 | 9 Oct 17 | 5,750,000
| 19,658,334
| 0.62% |
John Hawkins (i) | Financial Controller | 11 Sept 17 | 9 Oct 17 | 400,000
| 1,600,000
| 0.05% |
Julian Howell | Chief Medical Officer | 11 Sept 17 | 9 Oct 17 | 5,566,667
| 21,474,243
| 0.68% |
Shaun Stapleton | Head of Regulatory Affairs | 11 Sept 17 | 9 Oct 17 | 4,533,333
| 17,461,363
| 0.55% |
John Sinden | Chief Scientific Officer | 11 Sept 17 | 9 Oct 17 | 2,983,333
| 21,599,743
| 0.68% |
The LTIP awards are share options granted at nominal value and are subject to a three-year holding period, exercisable from the third anniversary of the award. The options are exercisable subject to the achievement of the following performance conditions:
1) When the first patient is administered with a ReNeuron cell therapy in an eighth clinical trial, one third of the options will vest.
2) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
3) If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
(i) The grant to Mr Hawkins was made under the Company's Employee Share Option Plan and is exercisable subject to achievement of performance conditions (1) and (2) above, with 50% of the options vesting in each case.
ENDS
ENQUIRIES:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer
| |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Cowles, Stephanie Watson
| |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
| |
Nplus1 Singer Advisory LLP | +44 (0) 20 7496 3000 |
Mark Taylor (Joint Broker) |
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Randolph Corteling | ||||
2 | Reason for the notification | |||||
a) | Position/status | Head of Research | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
(Disclosure in relation to share options granted and accepted by Directors and PDMRs)
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Sharon Grimster | ||||
2 | Reason for the notification | |||||
a) | Position/status | VP Development & General Manager - Wales | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | John Hawkins | ||||
2 | Reason for the notification | |||||
a) | Position/status | Financial Controller | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Julian Howell | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Medical Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Shaun Stapleton | ||||
2 | Reason for the notification | |||||
a) | Position/status | Head of Regulatory Affairs | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | John Sinden | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Scientific Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Olav Hellebo | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Michael Hunt | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | John Berriman | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Chairman | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Simon Cartmell | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Tim Corn | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Claudia D'Augusta | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Chris Evans | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Mike Owen | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Grant of share options | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | N/A | ||||
e) | Date of the transaction | Granted 11 September 2017; Deemed accepted 9 October 2017 | ||||
f) | Place of the transaction | Outside a trading venue | ||||